HCG2026-04-012026-06-30HCG2026-06-30HCG2026-04-012026-06-30in-capmkt:OtherExpenses1MemberHCG2026-04-012026-06-30in-capmkt:OtherExpenses2MemberHCG2026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1HCG2026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss2HCG2026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1HCG2026-04-012026-06-30ItemsThatWillBeReclassifiedToProfitAndLoss2HCG2026-04-012026-06-30AuditorDomain1HCG2026-06-30Statement1HCG2026-04-012026-06-30Statement1HCG2026-06-30StatementDynamic1I1Statement1HCG2026-06-30StatementDynamic1I2Statement1HCG2026-06-30StatementDynamic1I3Statement1HCG2026-06-30StatementDynamic1I4Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares539787HCGNOTLISTEDINE075I01017Healthcare Global Enterprises LimitedMain BoardEquity2026-04-012027-03-312026-08-062026-07-27INRLakhsQuarterlyFirst quarterSingle segmentHealthcare2026-08-0611:30:002026-08-0618:50:00Declaration of unmodified opiniontrue1falseThe compnay has not defaulted in repayment of loans. The Company has not issued debt securities.2026-04-012026-06-30UnauditedStandalone37666000009560000038622000000956100000-36000000596700000217300000395700000165760000037874000007480000007480000036200000-17200000190000000558000000000558000000558000001493000000100.370.37000.370.37Medical consultancy charges773400000Other expenses884200000Remeasurements of the defined benefit plans0Income tax effect on above000Effective portion of gain on hedging instruments in cash flow hedge0Income tax effect on above0000UnauditedtrueB S R & Co. LLPtrue2028-07-31Rights Issues2026-03-2742468180002026-06-30trueCare Ratings LimitedfalseNILNILNILSunu ManuelCompany SecretaryBangalore2026-08-06Pre-payment and/ or repayment of all, or a portion of, certain outstanding borrowings availed by our Company and by one of our wholly owned Subsidiaries, HCG NCHRI Oncology LLPNA1700000000017000000000Part-payment of consideration for acquisition of 34.00% additional stake in equity share capital of Vizag Hospital and Cancer Research Center Private Limited, one of our existing SubsidiariesNA1540396000015403960000General corporate purposes*#NA95568700009583430002656000The actual Issue Related Expenses incurred were Rs. 4.81 crore as against the estimated allocation of Rs. 5.07 crore. Consequently, the unutilized amount of Rs. 0.26 crore was utilized towards General Corporate Purposes, resulting in utilization of Rs. 95.83 crore (which is less than 25% of the total issue size) under General Corporate Purposes as compared to the originally allocated amount of Rs. 95.57 crore. There was no change in the overall utilization of the net proceeds from the Issue. Please note that the aforesaid utilization is in accordance with the disclosures set out in the Offer Document and is within the overall limit prescribed under the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.Issue related expenses**NA507350000480780002656000The actual Issue Related Expenses incurred were Rs. 4.81 crore as against the estimated allocation of Rs. 5.07 crore. Consequently, the unutilized amount of Rs. 0.26 crore was utilized towards General Corporate Purposes, resulting in utilization of Rs. 95.83 crore (which is less than 25% of the total issue size) under General Corporate Purposes as compared to the originally allocated amount of Rs. 95.57 crore. There was no change in the overall utilization of the net proceeds from the Issue. Please note that the aforesaid utilization is in accordance with the disclosures set out in the Offer Document and is within the overall limit prescribed under the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.